Previous 10 | Next 10 |
The European Commission (EC) approved PTC Therapeutics' ( NASDAQ: PTCT ) one-time gene replacement therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. The company said Upstaza (eladocagene exuparvovec) i...
Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency PR Newswire - PTC Therapeutics to launch first gene therapy directly administered into the brain - SOUTH PLAINFIELD, N.J. ,...
PTC Therapeutics shares made a >40% gain this week after its Duchenne Muscular Dystrophy drug Translarna reported data from a late-stage trial. The issue may be that the drug did not meet its primary endpoint, which makes an FDA approval unlikely and may put sales of the drug in Eu...
RBC Capital analyst Brian Abrahams raised PTC Therapeutics (NASDAQ:PTCT) price target to $46 from $42 and maintained a Sector Perform rating on the shares. This update is followed by phase 3 study 041 data, increasing the probability that Translarna remains on the E.U. market to 95% from...
PTC Therapeutics (NASDAQ:PTCT), a biotech focused on rare diseases added ~27% in the pre-market Tuesday after disclosing topline data from a placebo-controlled trial for Translarna (ataluren), a drug targeted at patients with nonsense mutation Duchenne muscular dystrophy. According ...
PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy PR Newswire SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDA...
Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors PR Newswire SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's ...
PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference PR Newswire SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at...
Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study PR Newswire - Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOU...
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old PR Newswire - Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, chi...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....